Joerg Christian Schefold

Joerg Christian Schefold

Auto-generated profile, based on publicly available information

Joerg Christian Schefold

Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CMChristian Meisel
Christian Meisel
JSJoerg C. Schefold
Joerg C. Schefold
RPRene Pschowski
Rene Pschowski
TBTycho Baumann
Tycho Baumann
KHKatrin Hetzger
Katrin Hetzger
HVHans-Dieter Volk
Hans-Dieter Volk
Rationale: Sustained sepsis-associated immunosuppression is associated with uncontrolled infection, multiple organ dysfunction, and death. Objectives: In the first controlled biomarker-guided immunostimulatory trial in sepsis, we tested whether granulocyte–macrophage colony-stimulating factor (GM-CSF) reverses monocyte deactivation, a hallmark of sepsis-associated immunosuppression (primary endpoint), and improves the immunological and clinical course of patients with sepsis. Methods: In a prospective, randomized, double-blind, placebo-controlled, multicenter trial, 38 patients (19/group) with severe sepsis or septic shock and sepsis-associated immunosuppression (monocytic HLA-DR [mHLA-DR] <8,000 monoclonal antibodies (mAb) per cell for 2 d) were treated with GM-CSF (4 μg/kg/d) or placebo for 8 days. The patients' clinical and immunological course was followed up for 28 days. Measurements and Main Results: Both groups showed comparable baseline mHLA-DR levels (5,609 ± 3,628 vs. 5,659 ± 3,332 mAb per cell), which significantly increased within 24 hours in the GM-CSF group. After GM-CSF treatment, mHLA-DR was normalized in 19/19 treated patients, whereas this occurred in 3/19 control subjects only (P < 0.001). GM-CSF also restored ex-vivo Toll-like receptor 2/4–induced proinflammatory monocytic cytokine production. In patients receiving GM-CSF, a shorter time of mechanical ventilation (148 ± 103 vs. 207 ± 58 h, P = 0.04), an improved Acute Physiology and Chronic Health Evaluation-II score (P = 0.02), and a shorter length of both intrahospital and intensive care unit stay was observed (59 ± 33 vs. 69 ± 46 and 41 ± 26 vs. 52 ± 39 d, respectively, both not significant). Side effects related to the intervention were not noted. Conclusions: Biomarker-guided GM-CSF therapy in sepsis is safe and effective for restoring monocytic immunocompetence. Use of GM-CSF may shorten the time of mechanical ventilation and hospital/intensive care unit stay. A multicenter trial powered for the improvement of clinical parameters and mortality as primary endpoints seems indicated. Clinical trial registered with www.clinicaltrials.gov (NCT00252915).

30 August 2016 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
JSJoerg C. Schefold
Joerg C. Schefold
GFGerasimos Filippatos
Gerasimos Filippatos
GHGerd Hasenfuss
Gerd Hasenfuss
SAStefan D. Anker
Stefan D. Anker
SHStephan von Haehling
Stephan von Haehling

29 November 2019 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
BGBertrand Guidet
Bertrand Guidet
DLDylan W. de Lange
Dylan W. de Lange
ABAriane Boumendil
Ariane Boumendil
SLSusannah Leaver
Susannah Leaver
XWXimena Watson
Ximena Watson
HFHans Flaatten
Hans Flaatten

28 March 2019 in Critical Care
Verified
Journal Article
Open access
PDF file
PZPatrick Zuercher
Patrick Zuercher
CMCéline S. Moret
Céline S. Moret
RDRainer Dziewas
Rainer Dziewas
JSJoerg C. Schefold
Joerg C. Schefold
Dysphagia may present in all critically ill patients and large-scale clinical data show that e.g. post-extubation dysphagia (PED) is commonly observed in intensive care unit (ICU) patients. Recent data demonstrate that dysphagia is mostly persisting and that its presence is independently associated with adverse patient-centered clinical outcomes. Although several risk factors possibly contributing to dysphagia development were proposed, the underlying exact mechanisms in ICU patients remain incompletely understood and no current consensus exists on how to best approach ICU patients at risk. From a clinical perspective, dysphagia is well-known to be associated with an increased risk of aspiration and aspiration-induced pneumonia, delayed resumption of oral intake/malnutrition, decreased quality of life, prolonged ICU and hospital length of stay, and increased morbidity and mortality. Moreover, the economic burden on public health care systems is high. In light of high mortality rates associated with the presence of dysphagia and the observation that dysphagia is not systematically screened for on most ICUs, this review describes epidemiology, terminology, and potential mechanisms of dysphagia on the ICU. Furthermore, the impact of dysphagia on affected individuals, health care systems, and society is discussed in addition to current and future potential therapeutic approaches.

1 December 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
IRIgnacio Rubio
Ignacio Rubio
MOMarcin F Osuchowski
Marcin F Osuchowski
MSManu Shankar-Hari
Manu Shankar-Hari
TSTomasz Skirecki
Tomasz Skirecki
MWMartin Sebastian Winkler
Martin Sebastian Winkler
JBJesús F. Bermejo-Martin
Jesús F. Bermejo-Martin

6 December 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MKMette Krag
Mette Krag
SMSøren Marker
Søren Marker
APAnders Perner
Anders Perner
JWJørn Wetterslev
Jørn Wetterslev
MWMatt P. Wise
Matt P. Wise
MMMorten H. Møller
Morten H. Møller
Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear. In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary outcome was death by 90 days after randomization. A total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole group and 1653 to the placebo group. Data on the primary outcome were available for 3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 0.91 to 1.13; P=0.76). During the ICU stay, at least one clinically important event (a composite of clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection, or myocardial ischemia) had occurred in 21.9% of patients assigned to pantoprazole and 22.6% of those assigned to placebo (relative risk, 0.96; 95% CI, 0.83 to 1.11). In the pantoprazole group, 2.5% of patients had clinically important gastrointestinal bleeding, as compared with 4.2% in the placebo group. The number of patients with infections or serious adverse reactions and the percentage of days alive without life support within 90 days were similar in the two groups. Among adult patients in the ICU who were at risk for gastrointestinal bleeding, mortality at 90 days and the number of clinically important events were similar in those assigned to pantoprazole and those assigned to placebo. (Funded by Innovation Fund Denmark and others; SUP-ICU ClinicalTrials.gov number, NCT02467621.)